Resalis Therapeutics

Resalis in a nutshell: We have summarized key facts about our company in a comprehensive factsheet. This resource includes essential scientific data, an explanation of our pioneering non-coding RNA approach, and the next steps for our lead candidate, RES-010. We invite you to explore our journey and the transformative potential of our work in metabolic diseases. Stay tuned for more updates and breakthroughs from Resalis!

Happy World RNA Day! 🧬 Did you know August 1st was chosen as World RNA Day because of the clever pun with AUG (adenine, uracil, and guanine), a codon that initiates protein synthesis? At Resalis, we're celebrating this day by highlighting our innovative non-coding RNA approach to tackling obesity. Unlike GLP-1 agonists, our approach does not suppress appetite. Instead, it focuses on the root causes of metabolic diseases by converting white adipose tissue to brown, increasing energy expenditure and cellular metabolism. Resalis is not just developing another treatment option; we aim to address significant gaps in current therapies and make a lasting impact in people’s lives. Join us in recognizing the incredible potential of RNA in transforming healthcare!

At Resalis, we possess a deep understanding of non-coding RNA and metabolic diseases, equipping us to address prevalent misconceptions surrounding disease treatment. Let us debunk some common myths regarding the management of metabolic diseases: MYTH VS. FACT Myth: All treatments for metabolic diseases are focused on controlling diet and exercise. ·       Fact: While lifestyle changes are fundamental, research like that conducted by Resalis, introduces biochemical interventions targeting specific molecules, offering supportive therapeutic options that address underlying biological causes. Myth: Lasting treatments for metabolic diseases are always invasive and have severe side effects. ·       Fact: While significant advances have been made in the last year, noninvasive treatment options like GLP-1 antagonists still have side effects and long-term consequences that we are only starting to understand. Resalis is specifically working on addressing these side effects and developing therapeutic options that provide patients with lasting weight loss even after stopping the medication. Myth: Once diagnosed with a metabolic disease, the progression is irreversible. ·       Fact: Emerging therapies are showing promise in halting and potentially reversing the progression of conditions such as obesity and MAFLD, underscoring the importance of ongoing research and innovation in treatment strategies. By challenging misconceptions about metabolic disease management, Resalis aims to overcome current treatment limitations and develop RES-010 as a transformative approach to treating metabolic disorders.

Just last week Riccardo Panella, Resalis’ CSO, delivered an oral presentation at the International Congress on Obesity in São Paul, Brazil. Organized by the World Obesity Federation, this event showcased new research and emerging strategies to tackle obesity. In his presentation, Riccardo highlighted how targeting non-coding RNA can enhance the efficacy of GLP1-R agonists in treating obesity and other metabolic disorders. Check out some highlights from his presentation below and the full poster on our website: https://lnkd.in/dRgwx6Yq

Exciting Opportunity: Join Our Team as a Publications Lead! 🌟 We are thrilled to announce an opening for a dynamic and experienced Publications Lead to join Resalis Therapeutics on a part-time or consultant basis! If you are 🚀 passionate about scientific communication and have a proven track record in managing publications within the biotech or pharmaceutical industry, we want to hear from you! 💥

Today we want to celebrate the fact that our CSO, Riccardo Panella, has published three impactful papers in 2023, shedding light on the critical role of microRNA-22 and the benefits of inhibiting it with our antisense oligonucleotide, RES-010. These publications underline the promising therapeutic benefits of RES-010 in treating metabolic disorders and potentially even cancer. We are excited about the future and the impact this research will have on patients’ lives. These are his publications: 1.    MicroRNA-22 is a Key Regulator of Lipid and Metabolic Homeostasis, International Journal of Molecular Science 2.    Assessment of Immunostimulatory Responses to the antimiR-22 Oligonucleotide Compound RES-010 in Human Peripheral Blood Mononuclear Cells, Frontiers in Pharmacology. 3.    Targeting of MicroRNA-22 Suppresses Tumor Spread in a Mouse Model of Triple-Negative Breast Cancer, Biomedicines

Resalis Therapeutics is tackling metabolic disorders with the power of non-coding RNAs! Their research on RES-010 shows promise for obesity treatment. Top startup for a reason! Learn more: https://lnkd.in/ess48Zc #ItalianStartups #HealthTech #BioTech

At Resalis, we aim to harness the body’s physiology to effectively combat obesity and achieve lasting results. Our new mode of action video explains how our lead program, RES-010, targets the underlying mechanism. Metabolic diseases are regulated through multiple cellular pathways. Instead of finding a high-precision downstream target, we have identified an important upstream player who is orchestrating multiple pro-lipogenic programs. Our product candidate RES-010 specifically targets this central player, miR-22, enabling the transformation of white adipose tissue into brown adipose tissue. It increases fatty acid oxidation and energy expenditure and reduces lipid biosynthesis. Therefore, it specifically increases cellular metabolism and decreases only fat mass.

At Resalis, we aim to harness the body’s physiology to effectively combat obesity and achieve lasting results. Our new mode of action video explains how our lead program, RES-010, targets the underlying mechanism. Metabolic diseases are regulated through multiple cellular pathways. Instead of finding a high-precision downstream target, we have identified an important upstream player who is orchestrating multiple pro-lipogenic programs. Our product candidate RES-010 specifically targets this central player, miR-22, enabling the transformation of white adipose tissue into brown adipose tissue. It increases fatty acid oxidation and energy expenditure and reduces lipid biosynthesis. Therefore, it specifically increases cellular metabolism and decreases only fat mass.

Once considered a problem only in high-income countries, overweight and obesity are on the rise worldwide. In 2022, over 390 million children and adolescents aged 5-19 were overweight, highlighting a growing global health crisis. Childhood obesity not only increases the risk of serious comorbidities such as diabetes and cardiovascular diseases but also has severe psychosocial consequences. It negatively impacts school performance and quality of life, often compounded by stigma, discrimination, and bullying. Furthermore, many affected children face a double burden of malnutrition, dealing with both undernutrition and obesity, exacerbating health risks. At Resalis, we are developing therapeutic options that do not foster weight loss by reducing appetite but aim to promote metabolic changes, specifically converting white adipose tissue to brown adipose tissue, thereby increasing energy usage and enabling a lasting weight loss effect.